

NEUROLOGIX INC/DE
Form NT 10-Q
November 15, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING

OMB APPROVAL
OMB Number: 3235-0058
Expires: April 30, 2012
Estimated average burden hours per response 2.50
SEC FILE NUMBER
000-13347
CUSIP NUMBER
64125U406

(Check one): Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D Form N-SAR Form N-CSR

For Period Ended: September 30, 2011

Transition Report on Form 10-K
 Transition Report on Form 20-F
 Transition Report on Form 11-K
 Transition Report on Form 10-Q
 Transition Report on Form N-SAR
For the Transition Period Ended:

Read
Instructions
(on back
page) Before
Preparing
Form. Please
Print or
Type.
Nothing in
this form
shall be
construed to
imply that
the
Commission
has verified
any
information
contained
herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

Neurologix, Inc.
Full Name of Registrant

Arinco Computer Systems Inc. (formerly known as Change Technology Partners, Inc.)
Former Name if Applicable

One Bridge Plaza
Address of Principal Executive Office (Street and Number)

Fort Lee, New Jersey 07024
City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Neurologix, Inc. (the "Company") is unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 (the "10-Q") by November 14, 2011 (the "Filing Deadline"). As disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on October 31, 2011, the Company will need to obtain additional funds to be able to continue its operations, and may not be in a position to continue beyond the end of November 2011 without such funds. The Company's management has had to devote substantially all of its efforts to raising additional capital and the Company did not have adequate time to complete the preparation of its financial statements for the quarter ended September 30, 2011 by the Filing Deadline without unreasonable effort or expense. If the Company's capital raising efforts are successful, the Company will file the 10-Q as soon as practicable.

SEC 1344 Persons who are to respond to the collection of information contained in this form are not
(03-05) required to respond unless the form displays a currently valid OMB control number.

(Attach extra Sheets if Needed)

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Marc L. Panoff
(Name)

(201)
(Area Code)

592-6451
(Telephone
Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
x Yes o No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
o Yes x No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Neurologix, Inc.
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date November 15, 2011

By /s/ Marc L. Panoff
Chief Financial Officer, Secretary and Treasurer

ATTENTION

Intentional
misstatements
or omissions
of fact
constitute
Federal
Criminal
Violations
(See 18 U.S.C.
1001).

